480 related articles for article (PubMed ID: 26916000)
1. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
3. Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity.
Backe SJ; Woodford MR; Ahanin E; Sager RA; Bourboulia D; Mollapour M
Subcell Biochem; 2023; 101():319-350. PubMed ID: 36520312
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones.
Li J; Soroka J; Buchner J
Biochim Biophys Acta; 2012 Mar; 1823(3):624-35. PubMed ID: 21951723
[TBL] [Abstract][Full Text] [Related]
5. Structure, function and regulation of the hsp90 machinery.
Li J; Buchner J
Biomed J; 2013; 36(3):106-17. PubMed ID: 23806880
[TBL] [Abstract][Full Text] [Related]
6. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
7. Post-translational modifications of Hsp90 and translating the chaperone code.
Backe SJ; Sager RA; Woodford MR; Makedon AM; Mollapour M
J Biol Chem; 2020 Aug; 295(32):11099-11117. PubMed ID: 32527727
[TBL] [Abstract][Full Text] [Related]
8. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
Prodromou C
Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
[TBL] [Abstract][Full Text] [Related]
9. The chaperone Hsp90: changing partners for demanding clients.
Röhl A; Rohrberg J; Buchner J
Trends Biochem Sci; 2013 May; 38(5):253-62. PubMed ID: 23507089
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
12. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
13. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
14. Post-translational modifications of Hsp90 and their contributions to chaperone regulation.
Mollapour M; Neckers L
Biochim Biophys Acta; 2012 Mar; 1823(3):648-55. PubMed ID: 21856339
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
16. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
17. Detecting Posttranslational Modifications of Hsp90.
Sager RA; Woodford MR; Neckers L; Mollapour M
Methods Mol Biol; 2018; 1709():209-219. PubMed ID: 29177662
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
19. The Hsp90 molecular chaperone: an open and shut case for treatment.
Pearl LH; Prodromou C; Workman P
Biochem J; 2008 Mar; 410(3):439-53. PubMed ID: 18290764
[TBL] [Abstract][Full Text] [Related]
20. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.
Woodford MR; Dunn DM; Blanden AR; Capriotti D; Loiselle D; Prodromou C; Panaretou B; Hughes PF; Smith A; Ackerman W; Haystead TA; Loh SN; Bourboulia D; Schmidt LS; Marston Linehan W; Bratslavsky G; Mollapour M
Nat Commun; 2016 Jun; 7():12037. PubMed ID: 27353360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
